Targeting IgA Nephropathy (Sponsored Content)

Summary

---

Podcast Summary: Masters in Business – "Targeting IgA Nephropathy"

Podcast: Masters in Business (Bloomberg)
Episode: Targeting IgA Nephropathy (Sponsored Content)
Date: November 9, 2025
Host: Jordan Goss Poirier (Bloomberg Media Studios)
Guests:

• Rachel Benton (Patient)
• Dr. Jonathan Barrett (University of Leicester)
• Mark Bunage (Vertex Pharmaceuticals)
• Dr. Manish Masky (Vertex Pharmaceuticals)

---

Overview

This episode of "Targeting the Toughest Diseases," produced by Bloomberg Media Studios and sponsored by Vertex Pharmaceuticals, delves into IgA nephropathy (IgAN), a rare and progressive kidney disease. Through the personal story of Rachel Benton, insights from leading nephrologists, and a look at innovative biotech research, the episode explores both the human and scientific challenges of diagnosing, living with, and ultimately seeking treatments for IgA nephropathy.

---

Key Discussion Points & Insights

1. Rachel’s Story: The Human Face of IgA Nephropathy

• Diagnosis by Accident:

  • Rachel Benton discovers she has IgA nephropathy after a routine urine test during her pregnancy reveals protein in her urine.
  • “We know it is IgA nephropathy. It's a rare kidney disease. There is not a cure. We don't have a cause.” (Rachel Benton, 01:34)
  • Rachel describes the shock, uncertainty, and distress following her diagnosis and the long-term impact on her daily life and family.

• Daily Life with IgAN:

  • Rachel manages her condition with diet changes and medication for blood pressure and cholesterol.
  • Experiences severe, chronic fatigue: “It's not just new mom tiredness, but debilitating fatigue, where she'll sleep for 12 hours and still need a midday nap.” (Narration, 05:51)
  • Emotional toll: Guilt about potential future health and being present for her son and husband.

2. Medical Insight: Understanding IgA Nephropathy

• What is IgA Nephropathy?

  • Dr. Jonathan Barrett explains:

    • IgA nephropathy is an underdiagnosed and historically under-researched chronic kidney disease.
    • The disease’s early symptoms are subtle and often picked up incidentally, typically by a routine urine test.
    • “Normally, the patients I see have no idea why they're coming to see a kidney doctor.” (Dr. Jonathan Barrett, 08:11)
    • IgA protein, meant to defend the body, accumulates in the kidneys, clogging filters and leading to inflammation, scarring, and kidney failure.

  • Genetic and Biological Complexity:

    • There’s suspected but unconfirmed genetic involvement.
    • Only definitive diagnosis: kidney biopsy.
    • The majority of adults with IgAN will progress to end-stage renal disease within 20 years of diagnosis, requiring dialysis or transplant.

  • Mental and Emotional Burden:

    • Unpredictability of disease progression causes constant anxiety:

      “The big challenge is actually the impact on mental wellness... That sense of uncertainty can be absolutely devastating for young people." (Dr. Barrett, 10:45)

3. Vertex Pharmaceuticals: Innovating for IgAN Treatment

• Vertex’s Approach:

  • Mark Bunage (Vertex):
    • Focus on serious diseases with significant unmet needs, leveraging scientific innovation.
    • “We focus on causal human biology and on human validated targets… we are completely modality agnostic. We'll use whatever is the right tool in the toolbox… to come up with a transformative therapy.” (Mark Bunage, 12:16)

• Scientific Advances:

  • Dr. Manish Masky (Vertex):
    • Loss of control in B cells triggers IgAN.
    • Proteins BAF and APRIL are key drivers in B cell misregulation.
    • “BAF and APRIL really seem to be two of the most critical proteins driving this transition from something that would protect us to something that would actually make antibodies that will harm our native tissues.” (Dr. Masky, 14:12)
    • Vertex aims to develop therapies targeting both BAF and APRIL to restore immune balance, potentially halting disease progression.

4. Advocacy and Advice

• Rachel advocates for regular urine testing as a simple measure for early detection:

  • “All of my friends, because of this, I'm like, please get your yearlies done, but also ask for that urine test…” (Rachel Benton, 17:25)

• General advice: Kidney health should be a routine conversation with healthcare providers.

---

Notable Quotes & Memorable Moments

• Rachel on receiving her diagnosis:

  “I got off the phone and just cried. I think for probably two days straight.” (05:21)

• Dr. Barrett on the uncertainty of the disease:

  “Some patients do really well with IGA nephropathy and others end up on dialysis relatively quickly. And that's the bit we haven't quite worked out yet.” (09:10)

• Dr. Masky on scientific approach:

  “There's a need to cast the widest net to catch the main actors involved in in the pathogenesis of IgA nephropathy. What we hope to see with this approach is the potential to restore immune balance for our patients…” (15:27)

• Rachel on living with the uncertainty:

  “Some days I can be like, you know what? I am a lawyer. I got this. Everything's great. And other days it's like I am not okay. And I feel like I could just crawl under a rock and stay there.” (16:23)

---

Important Timestamps

• 01:11-01:46 – Rachel’s diagnosis and reaction
• 04:25-05:21 – Rachel’s uncertainty and emotional impact post-diagnosis
• 07:35-08:36 – Dr. Barrett: Symptoms, underdiagnosis, and initial presentation
• 09:45-10:39 – Dr. Barrett: Pathophysiology – how IgA harms kidneys
• 10:45-11:25 – Dr. Barrett: Psychological and life impact
• 12:07-12:38 – Mark Bunage: Vertex’s research philosophy
• 13:24-15:21 – Dr. Masky: B cell dysfunction, BAF and APRIL’s roles
• 16:23-17:25 – Rachel: Living with uncertainty, mental health, and advice for others

---

Conclusion

This episode effectively brings together the poignant story of a young mother impacted by a rare disease and the innovators in medicine working to change patient outcomes. IgA nephropathy, once “invisible” in medical research, is gaining new attention thanks to advances in understanding immune system dysfunction and companies like Vertex Pharmaceuticals pursuing transformative, targeted treatments. The episode closes with a call for awareness: early testing and proactive kidney health discussions can be life-changing.

---

Transcript

[A]

Since you're a subscriber to this Bloomberg podcast, we thought you'd be interested in a six episode sponsored podcast called Targeting the Toughest Diseases. Produced by Vertex Pharmaceuticals and Bloomberg Media Studios, it explores the innovative tools, methods and unique philosophy Vertex Pharmaceuticals is using to search for treatments for some of humanity's most challenging diseases. Here's a recent episode.

[B]

Two year olds are a handful. They're full of energy and full of laughter. A lot of work for sure, but also a source of joy.

[C]

I definitely feel my calling in life was to be a mother and I just feel so blessed to be able to have that opportunity to have a child. So it's been great.

[B]

That's Rachel Benton, also known as Stetson's mom.

[C]

Stetson is his name. Stetson Corey Benton. I've always liked unique names. I never knew of anyone named Stetson before.

[B]

The thing about Stetson is, and he doesn't even know this yet, but he may have already saved his mom's life. A routine medical test that Rachel only took because she was pregnant showed protein in her urine. That led to further tests, a biopsy, and eventually a phone call delivering a diagnosis.

[C]

It was a pretty quick conversation. We know it is IgA nephropathy. It's a rare kidney disease. There is not a cure. We don't have a cause.

[B]

The call was short, but for Rachel, it changed everything. Hi, I'm Jordan Gas Poure, a member of the University of Southern California's center for Health Journalism. This is Targeting the Toughest Diseases, a podcast produced by Bloomberg Media Studios and Vertex Pharmaceuticals. In this series we look at some of humanity's most challenging diseases and how Vertex is a Boston based biotech company, is using innovative tools, methods and a unique philosophy to search for treatments and cures. Today we're looking at immunoglobulin anepropathy, more commonly known as IgA nephropathy. It's a progressive chronic kidney disease that for too long was underreported and under researched. We'll talk to experts inside and outside of Vertex about the latest work being done in this field. But first, back to Rachel's story. At the age of 30, Rachel Benton was living a great life. She was a licensed mortgage broker running her own agency. She owned her own house. And that fall she. She decided to throw a big Halloween party.

[C]

And he came with one of our mutual friends and we sort of rekindled from there.

[B]

He was Tom, a guy she had dated on and off during her 20s.

[C]

And then it was the end of November of 2020 that he asked me to marry him.

[B]

A year later, they got married, and shortly after that, Rachel got pregnant. During her pregnancy, Rachel had regular medical checkups, including routine urine tests.

[C]

We did a urine test, a 24 hour urine test, and that's where you have to take this big jug home and you have to pee straight into this jug every time for 24 hours. And so I bring it to the doctor and they test it, and sure enough, they found protein in my urine.

[B]

The doctor told her she wasn't facing any immediate risk, so they agreed to put that result aside, focus on having a healthy baby, and that they would investigate further once the baby was born. Stetson Corey Benton was born in May, and as a new parent, Rachel's life instantly became a whirlwind.

[C]

Honestly, I completely even forgot about the kidney stuff.

[B]

But around the nine month mark, she reached out to her doctor, she retested her urine, which confirmed she still had protein in her urine. So they decided to do a kidney biopsy. A biopsy is where a doctor uses a long needle to extract tiny pieces of tissue so they can do further tests. Rachel got the results over the phone.

[C]

And he's like, you know, we did confirm some things. You have a rare kidney disease called IgA nephropathy, or IgAN. So my first question was, you know, what do I do now? How do I stop this? Is there a cure? You know, just thinking of anything, like, what's the next steps? What about medication, blah, blah, blah. And he's like, well, the answer to.

[B]

Almost all of her questions was, we're not sure or it depends.

[C]

I got off the phone and just cried. I think for probably two days straight. I just was overwhelmed with obviously the diagnosis and not knowing where this would take me in life, what the next, you know, 24 hours would look like. A year, 10 years, you know, how is this going to affect me and my day to day life and, and my son and my husband?

[B]

She's adjusted her diet and takes medication to address her blood pressure and cholesterol. But the progress of the disease is variable. At one point, Rachel's kidney function dropped 30 points over two months. The doctor told her that at that rate, she'd be needing dialysis within a year. She's rebounded, but she doesn't know if that recovery will hold. She also deals with fatigue, not just new mom tiredness, but debilitating fatigue, where she'll sleep for 12 hours and still need a midday nap. In fact, Rachel says that for a couple of years before her diagnosis, she was Already dealing with extreme tiredness, but never really considered it a medical condition or something that needed attention. In hindsight, she wishes she had gotten it checked out. Looking forward, her long term health and her ability to be the kind of mom she wants to be is uncertain.

[C]

I have my days where I just feel very, very guilty being a mother to him with a rare disease and not knowing in a year, 10 years, however long, how I'm going to be and how active I get to be in his life every day. I just try to make the best of it though, and you know, whatever he wants to do. I put on a smile and try to push through.

[B]

Immunoglobulin. A nephropathy, or igan, is not a high profile disease. It's a chronic kidney disease that historically has not been well understood. But that's changing.

[D]

So I do clinics, so I see patients with glomerular disease, I run clinical trials and I have my research work at the university in the laboratory.

[B]

That's Dr. Jonathan Barrett. He's based at the University of Leicester in England and is a world renowned leader in kidney research.

[D]

So most of my career, no one was really interested in IGA nephropathy apart from a few people. Now it is. You can't move at a kidney meeting without people talking about IgA nephropathy.

[B]

One reason it was so under researched is that in the early stages, symptoms are often hard to detect.

[D]

Normally, the patients I see have no idea why they're coming to see a kidney doctor.

[B]

In many cases, it starts with an asymptomatic person having a urine test, like in Rachel's case with a routine urine test during pregnancy.

[D]

Perhaps you've joined a new gym. You get a physical, she wants to get a mortgage. You might have a job that requires you to have a physical and someone dips your urine and they say, oh, wait a minute, there's blood and protein in here.

[B]

Here's what we do know about the disease.

[D]

So each kidney contains about a million filters and they are continually filtering the blood to generate the urine. And in IgA nephropathy, this protein called IgA, starts sludging up those filters and stopping them from working properly. And if the filters don't work very well, they become leaky. And blood and protein can appear in.

[B]

The urine over time, sometimes months, sometimes years, your kidney function declines.

[D]

Some patients do really well with IGA nephropathy and others end up on dialysis relatively quickly. And that's the bit we haven't quite worked out yet.

[B]

In fact, we know the majority of adult patients with IgA nephropathy will progress to end stage kidney disease, which requires them to go on dialysis or get a transplant within 20 years of diagnosis. Dr. Barrett says there is evidence of a genetic component, but the connections aren't strong enough to do genetic screening. Right now, the only way to diagnose IgA nephropathy is with a kidney biopsy.

[D]

But what we think is that the major driver for this disease is the type of IGA we normally produce in our gut and in our respiratory tract. That normally gets into our sputum, into our tears, into our saliva. It's there to stop bugs entering the body, and it does a very, very good job. But in IgA nephropathy, some of that IgA actually gets into the bloodstream, but when it's in the bloodstream, it's a bit out of place, and it tends to stick to itself, to stick to other proteins. There are antibodies in the circulation it sticks to, and that forms these large what we call immune complexes, which are essentially big aggregates of protein. If you've got big globs of protein, it's completely reasonable to think that those globs of protein are going to start clogging up the filter, which is exactly what happens. And when they clog up the filter, there's inflammation, there's scarring, and that's what eventually causes kidney failure.

[B]

For people diagnosed with IgA nephropathy, the biological effects are only part of the problem.

[D]

The big challenge is actually the impact on mental wellness, because if you're a young person and I tell you, you've got this disease, it's incurable, there's a risk it could cause kidney failure in the future. But I can't tell you when you might need to go on dialysis or have a kidney transplant. But I can't tell you when. That sense of uncertainty can be absolutely devastating for young people. You imagine developing your career, wanting to pay that big amount of money for a house, getting married, thinking about children, and you have this threat hanging over you of a disease that the doctors can't really predict.

[B]

Addressing that fear and uncertainty requires showing patients there is a way forward. And that's what the team at Vertex is doing. IGA nephropathy represents exactly the kind of medical problem Vertex is targeting. There's a long history of research to build on. There's new technology available or versus Vertex thinks they can develop it. There's a large unmet need, and Vertex thinks it may be possible to tackle the underlying disease.

[E]

Simply put, Vertex's goal is to help people suffering from serious diseases. And we do that by investing in scientific innovation to create what we believe could be truly transformative medicines for people with these diseases.

[B]

That's Mark Bunage. He's the head of research at Vertex Pharmaceuticals and leads research on the company's pipeline of serious diseases.

[E]

We focus on causal human biology and on human validated targets. And then we ask the question, what's the right approach to take? And we are completely modality agnostic. We'll use whatever is the right tool in the toolbox, if you like, to address their biology and then to come up with a transformative therapy.

[B]

Earlier, Dr. Barrett explained how IgA nephropathy occurs. It's a buildup of what he calls big globs of protein that deposit and cause injury to the filters in your kidneys. But how can we stop that from happening? To answer that, I sat down with Dr. Manish Masky. He's a board certified nephrologist helping lead vertex's research into IgA nephropathy. Dr. Maskie explained that B cells, an important part of our immune system to fight off infections, can lose control and produce antibodies that hurt our own organs, in this case, the kidneys. Can you tell us a little bit about where the field is going and what's being done for people living with IgA nephropathy?

[F]

Absolutely. We now understand that loss of B cell control is what leads to the downstream mechanisms resulting in kidney injury and kidney function loss. So lots of research has been performed to try to understand what is influencing the B cell to lose control. It turns out that two proteins called BAF and April are key drivers.

[B]

Okay, so B cells are a type of white blood cel power our immune system. Can you tell us a little bit more about what BAF and April are and how they're involved in B cell control and how all of that relates to IgA nephropathy.

[F]

So first, Jordan, you're absolutely right that B cells, when they're doing what they're supposed to do, protect us from infections. They make antibodies that help us neutralize various pathogens. When B cells lose control, they can set off a cascade of events that result in processes that harm the body, so called autoimmune diseases. BAF and April are two similar but distinct proteins that control the life cycle of the B cell. So baff more in the early stage of development and maturation of the B cell and April more in the later stage of the B cell development. All the Way through to it becoming an antibody secreting cell. BAF in April really seem to be two of the most critical proteins driving this transition from something that would protect us to something that would actually make antibodies that will harm our native tissues.

[B]

This is a complex scenario. What's the innovative thinking that Vertex is considering here?

[F]

We know that the levels of bath in April are actually elevated in people with IgA nephropathy and that these levels correlate with measures of kidney function and damage. So through that, we believe both of these drivers are involved in uncontrolled B cells. Not Bath alone and not April alone. There's a need to cast the widest net to catch the main actors involved in in the pathogenesis of IgA nephropathy. What we hope to see with this approach is the potential to restore immune balance for our patients and give them the best chance at remission in the protein area, which is the protein spilling in the urine. Hematuria, which is the spilling of blood in the urine with associated stabilization of kidney function.

[B]

For Rachel Benton, living with uncertainty has become a constant burden.

[C]

It really scares me for my son. I feel like I let him down, I guess, you know, it's not fair for him to have a mom that is going to be sick for the rest of her life. It might not be bad today, but we don't know about tomorrow, you know, And I just. I feel guilt in that aspect of him just not having a healthy mom. Same for my husband. For him to have a wife that just isn't healthy. And it breaks my heart for them, really. But I try to stay positive and take care of myself as much as I can. But it definitely does play a huge role on your mental health, for sure, day to day. Some days I can be like, you know what? I am a lawyer. I got this. Everything's great. And other days it's like I am not okay. And I feel like I could just crawl under a rock and stay there.

[B]

Rachel, like a lot of people living with IgA nephropathy, has become an advocate, encouraging others to get checked.

[C]

All of my friends, because of this, I'm like, please get your yearlies done, but also ask for that urine test. You know, if you see any sign of protein in your urine, just double check it. Why not?

[B]

Exactly. Why not? Kidney health is not top of mind for most people, but it's worth talking to your doctor about. You can also go to Vertex's website, vrtx.com for more information on Vertex's commitment to IgA nephropathy and other serious kidney diseases. This is targeting the toughest Diseases, a podcast from Bloomberg Media Studios and Vertex Pharmaceuticals. If you like what you hear, subscribe and leave us a review. I'm Jordan Goss Poirier. Thanks for listening.